6101 related articles for article (PubMed ID: 20609178)
21. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
Spiegel DM; Khan I; Krishnan M; Mayne TJ
Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
[TBL] [Abstract][Full Text] [Related]
22. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
23. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
25. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
Dukkipati R; Kalantar-Zadeh K
Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
[TBL] [Abstract][Full Text] [Related]
26. The hematopoietic effect of Epotin (recombinant human erythropoietin-alpha) on maintenance hemodialysis end-stage kidney disease patients.
Al-Shohaib S; Shaker DS; Ghaedi BB; Alyarim M; Emara S; Behairy M
Transplant Proc; 2010 Apr; 42(3):753-9. PubMed ID: 20430164
[TBL] [Abstract][Full Text] [Related]
27. [Anemia treatment in peritoneal dialysis patients].
Janković N; Janković M
Acta Med Croatica; 2009 Sep; 63 Suppl 1():17-22. PubMed ID: 20232548
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
29. [Characteristics of anaemia treatment in children with chronic kidney disease].
Puretić Z
Acta Med Croatica; 2009 Sep; 63 Suppl 1():27-32. PubMed ID: 20235352
[TBL] [Abstract][Full Text] [Related]
30. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
31. [Managing anaemia in kidney transplant patients with chronic kidney disease].
López Oliva MO; Del Castillo Caba D; Fernández Fresnedo G
Nefrologia; 2009; 29 Suppl 1():25-30. PubMed ID: 19675658
[TBL] [Abstract][Full Text] [Related]
32. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M
Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and predictors of the sub-target Hb level in children on dialysis.
van Stralen KJ; Krischock L; Schaefer F; Verrina E; Groothoff JW; Evans J; Heaf J; Ivanov D; Kostic M; Maringhini S; Podracká L; Printza N; Pundziene B; Reusz GS; Vondrak K; Jager KJ; Tizard EJ;
Nephrol Dial Transplant; 2012 Oct; 27(10):3950-7. PubMed ID: 22740719
[TBL] [Abstract][Full Text] [Related]
34. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
35. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
36. Red blood cell survival in long-term dialysis patients.
Vos FE; Schollum JB; Coulter CV; Doyle TC; Duffull SB; Walker RJ
Am J Kidney Dis; 2011 Oct; 58(4):591-8. PubMed ID: 21715072
[TBL] [Abstract][Full Text] [Related]
37. Quality of care assessment and adherence to the international guidelines considering dialysis, water treatment, and protection against transmission of infections in university hospital-based dialysis units in Cairo, Egypt.
Ibrahim S
Hemodial Int; 2010 Jan; 14(1):61-7. PubMed ID: 19758297
[TBL] [Abstract][Full Text] [Related]
38. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
39. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
40. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns JS
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]